Experimental Drug Shows Promise in Slowing Disability from Multiple Sclerosis
Results of a phase 3 clinical trial show an experimental drug called tolebrutinib can delay disability in patients with non-relapsing secondary progressive multiple sclerosis.
Health News is provided as a service to Bowen Pharmacy site users by HealthDay. Bowen Pharmacy nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.